KDMN News and Press, Kadmon Holdings Inc. From 03/18/21

The following slide deck was published by Kadmon Holdings, Inc. in conjunction with this event. For further details see: Kadmon Holdings (KDMN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow

Dan Loeb's 13F portfolio value increased from ~$10B to ~$13B this quarter. The number of positions increased from 47 to 73. Third Point added Alphabet and increased Avantor and Planet Fitness while reducing Amazon.com and Alibaba Group Holdings. The top three positions are at ~20%...

Alto Ingredients (ALTO) -16% on Q4 earnings releaseMediciNova (MNOV) -16%.Savara (SVRA) -13% on proposed public offering of stockJust Energy Group (JE) -13% after announces Toronto Stock Exchange and New York Stock Exchange have commenced delisting proceedings.Enveric...

Kadmon Holdings (KDMN) announces that the U.S. FDA has extended the review period for the New Drug Application ((NDA)) for belumosudil for the treatment of chronic graft-versus-host disease ((cGVHD)). The action date has been extended to August 30, 2021.The FDA extended the PDUFA date to...

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD). ...

Kadmon (KDMN): Q4 GAAP EPS of -$0.17 misses by $0.01.Revenue of $0.62M (-85.9% Y/Y) beats by $0.18M.Shares -3% AH.Press Release For further details see: Kadmon EPS misses by $0.01, beats on revenue

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020. "With the acceptance of Kadmon's new drug application for belumosudil...

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities...

Kadmon Holdings' lead asset (KD025) has received a PDUFA date of May 30, 2021, for the treatment of cGvHD. Approval odds are solid after KD025 demonstrated overall response rates above 70% after the failure of two or more lines of systemic therapy. With the recent 13G support from...

Kadmon's cGVHD asset is Belumosudil. The molecule has shown a strong efficacy profile. The company has a strong cash balance. For further details see: Kadmon Looks Highly Investable Before PDUFA